The American Biotechnology Company Modern, specialized in Messenger RNA, announced this Monday the 94.5% efficacy of your coronavirus vaccine candidate. This announcement comes a week after US pharmaceutical company Pfizer and German biotechnology company BioNTech announce 90% effectiveness of their vaccine against COVID-19.
Stéphane Bancel, its CEO
The Moderna company has its headquarters in Cambridge, Massachusetts, United States, and its executive director is Stéphane Bancel since 2011. The company was founded in 2010 by Derrick Rossi, Canadian stem cell biologist and professor the Department of Stem Cells and Regenerative Biology, Harvard Medical School and is currently chaired by Stephen Hoge.
Before joining the American company, Bancel was executive director of the French diagnostic company bioMérieux SA for five years. From July 2000 to March 2006, he held various positions in the pharmaceutical Eli Lilly and Company, including that of general manager in Belgium and that of Executive Director of Global Manufacturing Strategy and Supply Chain. Before Lilly, it was also Asia Pacific Sales and Marketing Director for the biotechnology company bioMérieux.
“Our vaccine can prevent COVID-19”
In the company’s statement, the same CEO, Stéphane Bancel Has expressed: ”This is a crucial moment in the development of our COVID-19 candidate vaccine. Since the beginning of January, we have been pursuing this virus with the intention of protecting as many people as possible around the world. All along we have known that each day is important “, has added.
“This positive interim analysis from our phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease.”, Bencel concluded.
The income of the American company reached 60.2 million dollars during the year 2019. Moderna’s stock price was 103.5 dollars per share (about 87 euros) on Friday. In the last hours, The company has boosted its listing on the stock market above 15% in the operations prior to its opening.